PMID- 20738780
OWN - NLM
STAT- MEDLINE
DCOM- 20110217
LR  - 20181201
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 30
IP  - 9
DP  - 2010 Oct
TI  - Effects of terlipressin and somatostatin on liver and thorax blood volumes in 
      patients with cirrhosis.
PG  - 1371-8
LID - 10.1111/j.1478-3231.2010.02322.x [doi]
AB  - BACKGROUND: Variceal bleeding in cirrhosis can cause liver ischaemia and 
      deteriorate the hyperdynamic state; thus, the effects of vasoconstrictor therapy 
      on liver blood volume (LBV) and thorax blood volume (ThBV) are important. AIM: To 
      evaluate and compare the effects of terlipressin and somatostatin on LBV and ThBV 
      in stable patients with cirrhosis and portal hypertension. METHODS: Twenty 
      patients were studied (Child-Pugh class A/B/C: 5/8/7). The radioactivities in the 
      liver region (LRR) and the thorax region (ThRR) by single-head gamma camera 
      technique, as indicators of LBV and ThBV, respectively, and systemic 
      haemodynamics were measured at baseline and after intravenous infusion of 2 mg of 
      terlipressin (n=10) or somatostatin 250 mg/h after an initial bolus of 250 mg 
      (n=10). RESULTS: LRR and ThRR decreased significantly with increasing severity of 
      cirrhosis. Thirty minutes after terlipressin infusion, LRR and ThRR increased by 
      7.8 +/- 4.4% (NS) and 14 +/- 5.3% (P=0.01) compared with baseline values; the 
      increase in ThRR was significantly related to the increase in LRR (r=0.682, 
      P=0.03). In contrast, somatostatin reduced LRR and ThRR by 13.3 +/- 6.5% (P=0.07) 
      and 1 +/- 4% (NS) respectively. LRR and ThRR increased significantly in the 
      terlipressin group compared with the somatostatin group (P=0.01 and P=0.02 
      respectively). Terlipressin reduced cardiac output and heart rate (both P=0.01) 
      and increased the mean arterial pressure (MAP) and systemic vascular resistance 
      (P=0.009 and P=0.002 respectively); MAP decreased after somatostatin infusion 
      (P=0.03). CONCLUSIONS: Terlipressin, but not somatostatin, maintains LBV, 
      increases ThBV and improves the hyperdynamic state in cirrhosis. These effects 
      can be beneficial in variceal bleeding, particularly in patients with advanced 
      liver disease.
CI  - (c) 2010 John Wiley & Sons A/S.
FAU - Kalambokis, George
AU  - Kalambokis G
AD  - 1st Division of Internal Medicine, Medical School, University of Ioannina, 
      Ioannina, Greece.
FAU - Tsiouris, Spyridon
AU  - Tsiouris S
FAU - Tsianos, Epameinondas V
AU  - Tsianos EV
FAU - Baltayiannis, Gerasimos
AU  - Baltayiannis G
FAU - Pakou, Barbara
AU  - Pakou B
FAU - Fotopoulos, Andreas
AU  - Fotopoulos A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Hormones)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Vasoconstrictor Agents)
RN  - 50-57-7 (Lypressin)
RN  - 51110-01-1 (Somatostatin)
RN  - 7Z5X49W53P (Terlipressin)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
SB  - IM
MH  - Esophageal and Gastric Varices/drug therapy/etiology/physiopathology
MH  - Female
MH  - Gamma Cameras
MH  - Hemodynamics/drug effects
MH  - Hormones/*therapeutic use
MH  - Humans
MH  - Hypertension, Portal/complications/drug therapy/physiopathology
MH  - Infusions, Intravenous
MH  - Liver Circulation/*drug effects
MH  - Liver Cirrhosis/complications/*drug therapy/physiopathology
MH  - Lypressin/*analogs & derivatives/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals
MH  - Somatostatin/*therapeutic use
MH  - Technetium Tc 99m Sestamibi
MH  - Terlipressin
MH  - Thorax/*blood supply/diagnostic imaging
MH  - Vasoconstrictor Agents/*therapeutic use
EDAT- 2010/08/27 06:00
MHDA- 2011/02/18 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2011/02/18 06:00 [medline]
AID - LIV2322 [pii]
AID - 10.1111/j.1478-3231.2010.02322.x [doi]
PST - ppublish
SO  - Liver Int. 2010 Oct;30(9):1371-8. doi: 10.1111/j.1478-3231.2010.02322.x.